Novartis: EU approves Cosentyx for juvenile arthritis

(CercleFinance.com) - Novartis announced on Monday that the European Commission has given marketing approval for Cosentyx for the treatment of several forms of juvenile arthritis.


The green light from Brussels is for use in juvenile arthritis-related enthesitis (JRA) and juvenile psoriatic arthritis (JPA) in children over six years old.

This decision only covers young patients who have not improved sufficiently with existing treatments or who cannot tolerate them.

The Swiss biopharmaceutical company also unveiled on Monday new Phase III data for Kesimpta, its multiple sclerosis treatment.



Copyright (c) 2022 CercleFinance.com. All rights reserved.